Besides, the protective effect of DCHT on intrahepatic cholestasis with hepatotoxicity should be further explored in PPARα-null mice; or in the clinic, i.e., to be tested on intrahepatic cholestatic patients, and ultimately leading to the development of a new therapeutic strategy to treat intrahepatic cholestasis not extrahepatic cholestasis. Here, STK39 is linked to extrahepatic cholestasis.